LLY Jan 2025 600.000 call
| Previous Close | 61.37 |
| Open | 60.00 |
| Bid | 56.45 |
| Ask | 58.30 |
| Strike | 600.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 56.00 - 60.06 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 470 |
BloombergUpstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results
(Bloomberg) -- Structure Therapeutics Inc. jumped to a record high Friday after new data on its oral weight-loss drug fueled expectations that the San Francisco-based company is closing the gap with larger competitors such as Pfizer Inc.Most Read from BloombergPakistan Rupee Set to Become Top Performing Currency Globally Europe’s Richest Royal Family Builds $300 Billion Finance EmpireTop Chinese Scientist Claims India Moon Landing Nowhere Near South PoleUAW Aims For At Least 30% Wage Bump to Woo
Zacks3 Stocks to Focus on as Demand for Obesity Drugs Booms
With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market
ReutersEli Lilly settles whistleblower lawsuit over manufacturing problems
Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings. The former human resources officer, Amrit Mula, contended in the lawsuit that she repeatedly urged leaders at a New Jersey plant to remedy problems involving several biologic drugs, including Type 2 diabetes medicine Trulicity. Lilly called Mula a non-scientist whose allegations were "simply wrong," according to court filings.
